Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity.
The endogenous endocannabinoid system encompasses a family of natural signaling lipids ("endocannabinoids") functionally related to (9)-tetrahydrocannabinol, the psychoactive ingredient of marijuana (cannabis), along with proteins that modulate the endocannabinoids, including enzymes, transporters, and receptors. The endocannabinoid system's ubiquitous regulatory actions in health and disease underscore its importance to mammalian (patho)physiology and suggest discrete targets through which it may be modulated for therapeutic gain. Medications based on the endocannabinoid system are an important focus of contemporary translational research, particularly with respect to substance abuse and obesity, two prevalent disorders with a pathogenic component of endocannabinoid system hyperactivity. Pressing health care needs have made the rational design of targeted CB1 cannabinoid-receptor modulators a promising route to future medications with significant therapeutic impact against psychobehavioral and metabolic disturbances having a reward-supported appetitive component.
Janero
David R
DR
Center for Drug Discovery, Northeastern University, 116 Mugar Hall, 360 Huntington Avenue, Boston, MA 02115-5000, USA. d.janero@neu.edu
Makriyannis
Alexandros
A
D063385:Cannabinoid Receptor Modulators / Q000378:metabolism* / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000534:rehabilitation*; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects; D043882:Receptors, Cannabinoid / Q000187:drug effects*; D019966:Substance-Related Disorders / Q000534:rehabilitation*
D063385:Cannabinoid Receptor Modulators; D043884:Receptor, Cannabinoid, CB1; D043882:Receptors, Cannabinoid